Further inhibition of FGFR4 in drug-resistant cells revealed that the expression of SLC7A11 and GPX4 was significantly reduced, which promoted ferroptosis to inhibit tumorigenesis, thus restoring the sensitivity of drug-resistant breast cancer cells to anti-HER2 (Zou et al., 2022). This evidence concerns the gene ERBB2 and breast carcinoma.